An optional blood sample was collected from clinical trial subjects for pharmacogenetic analysis to investigate potential associations between genetic variants and varenicline response and general characteristics of smoking cessation. Sample collection was not required for participation in the original clinical trials; however, >50% of clinical trial subjects across all treatment arms volunteered to participate in the pharmacogenetic analysis.
